PortalPublikationenLong-term outcome of ABO-incompatible living donor kidney tr...

Long-term outcome of ABO-incompatible living donor kidney transplantation based on antigen-specific desensitization. An observational comparative analysis

Standard

Long-term outcome of ABO-incompatible living donor kidney transplantation based on antigen-specific desensitization. An observational comparative analysis. / Wilpert, Jochen; Fischer, Karl-Georg; Pisarski, Przemyslaw; Wiech, Thorsten; Daskalakis, Michael; Ziegler, Anna; Neumann-Haefelin, Elke; Drognitz, Oliver; Emmerich, Florian; Walz, Gerd; Geyer, Marcel.

in: NEPHROL DIAL TRANSPL, Jahrgang 25, Nr. 11, 01.11.2010, S. 3778-86.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Wilpert, J, Fischer, K-G, Pisarski, P, Wiech, T, Daskalakis, M, Ziegler, A, Neumann-Haefelin, E, Drognitz, O, Emmerich, F, Walz, G & Geyer, M 2010, 'Long-term outcome of ABO-incompatible living donor kidney transplantation based on antigen-specific desensitization. An observational comparative analysis', NEPHROL DIAL TRANSPL, Jg. 25, Nr. 11, S. 3778-86. https://doi.org/10.1093/ndt/gfq229

APA

Wilpert, J., Fischer, K-G., Pisarski, P., Wiech, T., Daskalakis, M., Ziegler, A., Neumann-Haefelin, E., Drognitz, O., Emmerich, F., Walz, G., & Geyer, M. (2010). Long-term outcome of ABO-incompatible living donor kidney transplantation based on antigen-specific desensitization. An observational comparative analysis. NEPHROL DIAL TRANSPL, 25(11), 3778-86. https://doi.org/10.1093/ndt/gfq229

Vancouver

Wilpert J, Fischer K-G, Pisarski P, Wiech T, Daskalakis M, Ziegler A et al. Long-term outcome of ABO-incompatible living donor kidney transplantation based on antigen-specific desensitization. An observational comparative analysis. NEPHROL DIAL TRANSPL. 2010 Nov 1;25(11):3778-86. https://doi.org/10.1093/ndt/gfq229

Bibtex

@article{17d181e6137d4182be70308a829d69fe,
title = "Long-term outcome of ABO-incompatible living donor kidney transplantation based on antigen-specific desensitization. An observational comparative analysis",
abstract = "BACKGROUND: ABO-incompatible living donor kidney transplantation based on specific conditioning has been successfully adopted by transplant centres worldwide. Excellent short-term results have been reported in small cohorts. However, long-term data and comparative analyses are still sparse. We report on the outcome of 40 consecutive ABO-incompatible living donor kidney transplant recipients and compare their clinical course to a control group of 43 ABO-compatible living donor transplant patients transplanted during the same time period.METHODS: This is an observational single-centre analysis of 40 consecutive patients undergoing ABO-incompatible kidney grafting between April 2004 and April 2009, using a protocol of rituximab, antigen-specific immunoadsorption, intravenous immunoglobulin, basiliximab induction and oral triple immunosuppression with tacrolimus, mycophenolic acid and prednisone. Forty-three ABO-compatible kidney transplant recipients served as controls. The control group had also received basiliximab induction and an identical initial maintenance immunosuppression. The two groups were observed for an average of 39 and 19 months, respectively.RESULTS: There was a significantly higher incidence of lymphoceles requiring surgical revisions in the ABO-incompatible group. However, this surgical complication did not affect patient or graft survival. Mean serum creatinine, estimated glomerular filtration rate and proteinuria did not differ between the two groups. Furthermore, ABO-incompatible and ABO-compatible patients had the same incidence of humoral and cellular rejections. Despite a more aggressive induction therapy, no differences in infectious or malignant complications were observed.CONCLUSIONS: ABO-incompatible living donor kidney transplantation utilizing a combination of rituximab and antigen-specific immunoadsorption yielded results identical to ABO-compatible transplantation despite a significantly higher number of human leukocyte antigen mismatches.",
keywords = "ABO Blood-Group System, Adolescent, Adult, Aged, Agglutinins, Blood Group Incompatibility, Desensitization, Immunologic, Female, Graft Rejection, Graft Survival, Humans, Immunosorbent Techniques, Kidney Transplantation, Living Donors, Male, Middle Aged, Prospective Studies",
author = "Jochen Wilpert and Karl-Georg Fischer and Przemyslaw Pisarski and Thorsten Wiech and Michael Daskalakis and Anna Ziegler and Elke Neumann-Haefelin and Oliver Drognitz and Florian Emmerich and Gerd Walz and Marcel Geyer",
year = "2010",
month = nov,
day = "1",
doi = "10.1093/ndt/gfq229",
language = "English",
volume = "25",
pages = "3778--86",
journal = "NEPHROL DIAL TRANSPL",
issn = "0931-0509",
publisher = "Oxford University Press",
number = "11",

}

RIS

TY - JOUR

T1 - Long-term outcome of ABO-incompatible living donor kidney transplantation based on antigen-specific desensitization. An observational comparative analysis

AU - Wilpert, Jochen

AU - Fischer, Karl-Georg

AU - Pisarski, Przemyslaw

AU - Wiech, Thorsten

AU - Daskalakis, Michael

AU - Ziegler, Anna

AU - Neumann-Haefelin, Elke

AU - Drognitz, Oliver

AU - Emmerich, Florian

AU - Walz, Gerd

AU - Geyer, Marcel

PY - 2010/11/1

Y1 - 2010/11/1

N2 - BACKGROUND: ABO-incompatible living donor kidney transplantation based on specific conditioning has been successfully adopted by transplant centres worldwide. Excellent short-term results have been reported in small cohorts. However, long-term data and comparative analyses are still sparse. We report on the outcome of 40 consecutive ABO-incompatible living donor kidney transplant recipients and compare their clinical course to a control group of 43 ABO-compatible living donor transplant patients transplanted during the same time period.METHODS: This is an observational single-centre analysis of 40 consecutive patients undergoing ABO-incompatible kidney grafting between April 2004 and April 2009, using a protocol of rituximab, antigen-specific immunoadsorption, intravenous immunoglobulin, basiliximab induction and oral triple immunosuppression with tacrolimus, mycophenolic acid and prednisone. Forty-three ABO-compatible kidney transplant recipients served as controls. The control group had also received basiliximab induction and an identical initial maintenance immunosuppression. The two groups were observed for an average of 39 and 19 months, respectively.RESULTS: There was a significantly higher incidence of lymphoceles requiring surgical revisions in the ABO-incompatible group. However, this surgical complication did not affect patient or graft survival. Mean serum creatinine, estimated glomerular filtration rate and proteinuria did not differ between the two groups. Furthermore, ABO-incompatible and ABO-compatible patients had the same incidence of humoral and cellular rejections. Despite a more aggressive induction therapy, no differences in infectious or malignant complications were observed.CONCLUSIONS: ABO-incompatible living donor kidney transplantation utilizing a combination of rituximab and antigen-specific immunoadsorption yielded results identical to ABO-compatible transplantation despite a significantly higher number of human leukocyte antigen mismatches.

AB - BACKGROUND: ABO-incompatible living donor kidney transplantation based on specific conditioning has been successfully adopted by transplant centres worldwide. Excellent short-term results have been reported in small cohorts. However, long-term data and comparative analyses are still sparse. We report on the outcome of 40 consecutive ABO-incompatible living donor kidney transplant recipients and compare their clinical course to a control group of 43 ABO-compatible living donor transplant patients transplanted during the same time period.METHODS: This is an observational single-centre analysis of 40 consecutive patients undergoing ABO-incompatible kidney grafting between April 2004 and April 2009, using a protocol of rituximab, antigen-specific immunoadsorption, intravenous immunoglobulin, basiliximab induction and oral triple immunosuppression with tacrolimus, mycophenolic acid and prednisone. Forty-three ABO-compatible kidney transplant recipients served as controls. The control group had also received basiliximab induction and an identical initial maintenance immunosuppression. The two groups were observed for an average of 39 and 19 months, respectively.RESULTS: There was a significantly higher incidence of lymphoceles requiring surgical revisions in the ABO-incompatible group. However, this surgical complication did not affect patient or graft survival. Mean serum creatinine, estimated glomerular filtration rate and proteinuria did not differ between the two groups. Furthermore, ABO-incompatible and ABO-compatible patients had the same incidence of humoral and cellular rejections. Despite a more aggressive induction therapy, no differences in infectious or malignant complications were observed.CONCLUSIONS: ABO-incompatible living donor kidney transplantation utilizing a combination of rituximab and antigen-specific immunoadsorption yielded results identical to ABO-compatible transplantation despite a significantly higher number of human leukocyte antigen mismatches.

KW - ABO Blood-Group System

KW - Adolescent

KW - Adult

KW - Aged

KW - Agglutinins

KW - Blood Group Incompatibility

KW - Desensitization, Immunologic

KW - Female

KW - Graft Rejection

KW - Graft Survival

KW - Humans

KW - Immunosorbent Techniques

KW - Kidney Transplantation

KW - Living Donors

KW - Male

KW - Middle Aged

KW - Prospective Studies

U2 - 10.1093/ndt/gfq229

DO - 10.1093/ndt/gfq229

M3 - SCORING: Journal article

C2 - 20466677

VL - 25

SP - 3778

EP - 3786

JO - NEPHROL DIAL TRANSPL

JF - NEPHROL DIAL TRANSPL

SN - 0931-0509

IS - 11

ER -